molecules molecules molecules molecules molecules molecules

Clinical Pipeline

Sort by:
Indication
Molecule
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
1L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen :
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Kidney Cancer

Line & Regimen :
1L
cas + zanza ± nivo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen :
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen :
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Advanced Malignancies

Line & Regimen :
2L+
cas
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
1L
AB598 ± zim + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen :
2L+
AB801 ± chemo + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:

Lung Cancer

Line & Regimen :
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen :
1L
dom ± zim ± FOLFOX
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen :
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen :
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Quemliclustat
(QUEMLI)

CD73 Inhibitor Small Molecule

Indication:

Lung Cancer

Line & Regimen :
1L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

GASTROINTESTINAL CANCER

Line & Regimen :
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen :
1L
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen :
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

Lung Cancer

Line & Regimen :
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen :
2L
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen :
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

CASDATIFAN
(CAS)

HIF-2𝛂 Inhibitor

Indication:

Advanced Malignancies, Including RCC

Line & Regimen :
2L+
cas
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Kidney Cancer

Line & Regimen :
1L
cas + zanza ± nivo
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

AB598

ANTI-CD39

Indication:

Advanced Malignancies

Line & Regimen :
1L
AB598 ± zim + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

AB801

AXL INHIBITOR

Indication:

Advanced Malignancies

Line & Regimen :
2L+
AB801 ± chemo + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Key Compounds Being Studied:
Casdatifan

HIF-2𝛂 Inhibitor

Etrumadenant

Dual A2aR/A2bR Antagonist Small Molecule

Quemliclustat

CD73 Inhibitor Small Molecule

Domvanalimab

anti-TIGIT mAb

Zimberelimab

anti-PD-1 mAb

Abbreviations:

cas: casdatifan; chemo: chemotherapy; dom: domvanalimab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; RCC: renal cell carcinoma; rego: regorafenib; zanza: zanzalintinib; zim: zimberelimab

*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

Partnerships & Collaborations